SCHEMBL3296269

SCHEMBL3296269

CN(C)CCN1C(=O)c2cccc3cc4c(NC(=O)CCCCl)cccc4c(c23)C1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 3/20 0.50
HEXA P06865 1/20 0.48
HEXB P07686 1/20 0.48
CYP2D6 P10635 2/20 0.47
HDAC3 O15379 4/20 0.46
HDAC4 P56524 4/20 0.46
HDAC1 Q13547 4/20 0.46
HDAC7 Q8WUI4 4/20 0.46
HDAC2 Q92769 4/20 0.46
HDAC10 Q969S8 4/20 0.46
HDAC11 Q96DB2 4/20 0.46
HDAC8 Q9BY41 4/20 0.46
HDAC6 Q9UBN7 4/20 0.46
HDAC9 Q9UKV0 4/20 0.46
HDAC5 Q9UQL6 4/20 0.46
NCOR2 Q9Y618 2/20 0.46
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3299639 0.91 FTO (0.51) FTOHEXAHEXBCYP2D6HDAC3
SCHEMBL3298476 0.88 HEXA (0.48) FTOHEXAHEXBCYP2D6ALDH1A1
SCHEMBL3296005 0.86 HEXA (0.55) FTOHEXAHEXBCYP2D6ALDH1A1
SCHEMBL17557149 0.86 HEXA (0.55) FTOHEXAHEXBCYP2D6ALDH1A1
SCHEMBL3297495 0.84 HEXA (0.45) FTOHEXAHEXBCYP2D6HDAC3
SCHEMBL3296770 0.84 HEXA (0.51) FTOHEXAHEXBCYP2D6ALDH1A1
SCHEMBL3303913 0.84 FTO (0.47) FTOHEXAHEXBCYP2D6ALDH1A1
SCHEMBL3295836 0.83 HEXA (0.47) FTOHEXAHEXBCYP2D6ALDH1A1
SCHEMBL3298835 0.83 FTO (0.46) FTOHEXAHEXBCYP2D6HDAC3
SCHEMBL5319917 0.82 FTO (0.69) FTOHEXAHEXBCYP2D6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741337-B2 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom UNIBIOSCREEN S.A. (BE) 2010-06-22 US disclosed
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom UNIBIOSCREEN S.A. (BE) 2008-11-27 US disclosed
EP-1787985-A1 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom Unibioscreen S.A. (BE) 2007-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 FTO 595/4885HEXA 1944/4885HEXB 2802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.